I've been in and out of IMCL several times myself, and yes, been waiting for that darn pullback. But I don't seen any new medical news for IMCL since the 4/14 mouse study. Prior to that, a tiny mention on 3/31, then the 3/9 broker upgrade and milestone payment. You have to go all the way back to 2/11 before you find the really significant news - which was the start of Phase 3 for C225. So I guess I'm saying that I don't see the "heavy news" to support a 100% price increase for the last few months. I know of at least several very respected "gurus" that called IMCL a "screaming short" above 16, and that it was a "no-brainer short" - and they are still waiting for that darn pullback :-)
We would of expected to see a very sharp sell-off in mid-March. But if you look at the chart, you see that IMCL is acting like a company that already makes money. The chart doesn't follow the conventional "small biotech news pop theory " at all in fact. About 2 months ago I wrote on the IMCL thread that I thought it was just possible that IMCL is a unique bird. A small biotech in phase 3 for a major cancer treatment - and it shouldn't be pigeon holed with all those pre-clinical cancer cure wannabee's.
My point was that once a biotech is brought to the forefront of investors minds and legitimized with broker analysis, the apparent risk of phase trial failure seems to fade away. IMCL is trading as if it's C225 is a guaranteed approval, which we all know isn't true. But the chance of approval is, indeed, quite high. I'd say that Theratope has as good, or perhaps even better, chance of approval. So there is a good chance that BIOM could achieve the same status shortly, and actually start holding greater gains. We're certainly doing better than last summer when we couldn't break $2.
Well, I will continue to watch IMCL as an indicator. I think successes by any and all small biotechs will ultimately boost the entire 3rd-4th biotech tier. There is a lot of gold hidden in them hills.
SM |
